Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection (Q43970020)

From Wikidata

Jump to navigation Jump to search

scientific article published on 6 September 2009

Language	Label	Description	Also known as
English	Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection	scientific article published on 6 September 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Plasmodium falciparum

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

W Ripley Ballou

26

object named as

W Ripley Ballou

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Marie-Claude Dubois

24

object named as

Marie-Claude Dubois

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Christian F Ockenhouse

4

object named as

Christian F Ockenhouse

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

D. Gray Heppner

27

object named as

D Gray Heppner

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

author name string

James F Cummings

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Michele D Spring

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Robert J Schwenk

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Kent E Kester

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Mark E Polhemus

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Douglas S Walsh

7

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

In-Kyu Yoon

8

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Christine Prosperi

9

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Laure Y Juompan

10

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

David E Lanar

11

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Urszula Krzych

12

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

B Ted Hall

13

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Lisa A Ware

14

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

V Ann Stewart

15

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Jack Williams

16

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Megan Dowler

17

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Robin K Nielsen

18

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Collette J Hillier

19

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Birgitte K Giersing

20

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Filip Dubovsky

21

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Elissa Malkin

22

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Kathryn Tucker

23

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Joe D Cohen

25

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

language of work or name

0 references

publication date

6 September 2009

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

5135-5144

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Molecular analysis of the association of HLA-B53 and resistance to severe malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Sequence variations in the non-repetitive regions of the liver stage-specific antigen-1 (LSA-1) of Plasmodium falciparum from field isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Non-CS pre-erythrocytic protective antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Malaria transmitted to humans by mosquitoes infected from cultured plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Phenotype and function of human T lymphocyte subsets: consensus and issues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

In vitro activity of CD4+ and CD8+ T lymphocytes from mice immunized with a synthetic malaria peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

CD8+ T cell contraction is controlled by early inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Interleukin-10 production by effector T cells: Th1 cells show self control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Aotus nancymaae as a potential model for the testing of anti-sporozoite and liver stage vaccines against Plasmodium falciparum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Defective adenoviruses as novel vaccines for the Flaviviridae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

Factors influencing resistance to reinfection with Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of age-dependent immunity to malaria in transmigrants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.046

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.08.046

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43970020&oldid=2105144760"